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use of serum creatinine to estimate GFR 
measurements. See page 652.
Bisphosphonates 
in uremic vascular 
calcification
Bisphosphonates are now widely used 
for the prevention of uremic vascular 
medial calcification. But whether they 
act on the blood vessels directly or on 
alteration of mineral metabolism and 
bone resorption is not known. Lomash-
vili et al. address this question. They 
induced uremia by administering ade-
nine to rats, which developed vascular 
calcification when fed a high-phospho-
rous diet. Daily administration of either 
of two bisphosphonates (etidronate or 
pamidronate) prevented aortic calci-
fication and reduced bone formation, 
while bone resorption was not signifi-
cantly affected. The authors then tested 
the effect of the medications on calcifi-
cation of rat aortas in vitro and found 
that these agents inhibited calcification 
in culture and arrested further calcifica-
tion of precalcified rats. It is now clear 
that calcification in the aortas occurs 
because the smooth muscle cells begin 
to express osteogenic proteins that play 
a large part in mediating this calcifica-
tion. Importantly, bisphosphonates did 
not affect the expression of these osteo-
genic factors or calcification inhibitors 
in vitro. The fact that these drugs can 
inhibit both uremic vascular calcifica-
tion and bone mineralization (each of 
them apparently directly) suggests that 
they act on a mechanism of calcification 
common to both of them. One possible 
result is the prevention of hydroxyapa-
tite formation. Thus, bisphosphonates 
may not prevent vascular calcification 
Cystatin C and GFR
The search for the best measurement of 
glomerular filtration rate (GFR) in epi-
demiological studies seems to be inex-
haustible. After serum creatinine was 
battered by large studies that have raised 
questions about its utility, the appear-
ance of cystatin C seems to have solved 
some of the problems. In a new study, 
Stevens et al. show associations between 
cystatin C and a number of lifestyle fac-
tors. The authors performed a cross-
sectional analysis of more than 3000 
clinical trial participants with chronic 
kidney disease in which both creati-
nine and cystatin C levels were meas-
ured as well as other clinical and routine 
laboratory parameters. Clearances of 
125I-iothalamate and 51Cr-EDTA were 
also measured as an estimate of GFR. 
Cystatin C as a measure of GFR was 
affected by age and sex; it was lower in 
women and as age advanced. Further, 
diabetes caused an apparent increase in 
cystatin C. Higher C-reactive protein, 
higher white blood cell count, and lower 
serum albumin were associated with 
higher levels of cystatin C and lower 
levels of creatinine. Adjustments for age, 
sex, and race had a greater effect on the 
association of factors with creatinine 
than cystatin C. These results raise the 
same questions that have plagued the 
without inhibiting bone formation in 
uremic rats. See page 617.
Vitamin D 
supplementation 
in renal transplant 
recipients
There is increasing evidence that vita-
min D is important for aspects of cellular 
metabolism other than mineral metabo-
lism, and that it has numerous beneficial 
effects. Now, the regulation of its plasma 
levels has acquired added significance. 
Specifically, serum levels of 25-hydroxy 
vitamin D were found to be frequently 
low following renal transplantation, the 
cause of which remains to be determined. 
In findings published in this issue, Cour-
bebaisse et al. examine the possibility of 
increasing 25-hydroxy vitamin D in trans-
plant recipients to bring the hormone 
levels closer to the normal range. The 
authors administered cholecalciferol every 
2 weeks for 2 months, followed by a dose 
every other month, to renal transplant 
recipients who had low vitamin D levels. 
After the initial phase, serum 25-hydroxy 
vitamin D levels were normalized, serum 
calcium levels normalized, and serum 
parathyroid hormone levels decreased in 
most patients. Serum 25-hydroxy vitamin 
D levels decreased after the initial intensive 
phase but remained higher in patients who 
received cholecalciferol compared with 
those who did not. These studies show 
that it is possible to raise levels of vitamin 
D, which will prevent metabolic anomalies 
that result from low vitamin D in trans-
plant patients. Although the reason these 
patients have low vitamin D levels remains 
unknown, immunosuppression therapy 
may play a role. See page 646.
